Wittington Ventures
VC Fund
Toronto, Canada
Wittington Ventures is a venture capital firm investing in the e-commerce/retail, healthcare and food sectors. We invest in companies throughout North America and at all stages of the start-up lifecycle. We are uniquely positioned to help entrepreneurs and their companies through strong affiliations with iconic Canadian brands such as Loblaw,Shoppers Drug Mart, Choice Properties, PC Financial, Joe Fresh and Selfridges Group.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Wittington Ventures invests in
Stages Wittington Ventures invests in
Countries Wittington Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Darian Zigante
|
|||
Jim Orlando
|
|||
Katie Hayes
|
|||
Megh Gupta
|
|||
Qasim Mohammad
|
Investment Focus
Industry
- Health Care 6 (21%)
- Artificial Intelligence 6 (21%)
- Biotechnology 5 (17%)
- Software 4 (14%)
- Life Science 4 (14%)
Stage
- Series A 7 (24%)
- Series C 6 (21%)
- Seed 5 (17%)
- Series B 5 (17%)
- Series D 1 (3%)
Country
- United States 11 (38%)
- Canada 6 (21%)
- Germany 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Darian Zigante
Senior Associate
|
Senior Associate | Total investments: 0 | Find email | |
|
Jim Orlando
Managing Partner
|
Managing Partner | Total investments: 15 | Find email | |
|
Katie Hayes
Director
|
Director | Total investments: 0 | Find email | |
|
Megh Gupta
Partner
|
Partner | Total investments: 5 | Find email | |
|
Qasim Mohammad
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Filament Sciences
|
Filament Sciences is a hair care company that researches and develops bond-building treatments designed to improve hair's tensile strength and repair structural damage at a molecular level. | $2M / Seed / Jun 02, 2026 | |
ViewsML
|
ViewsML leverages artificial intelligence to enhance virtual diagnostics and precision medicine. The company focuses on transforming spatial biology and translational research by utilizing virtual biomarkers. Their technology aims to improve patient outcomes by providing deeper insights into healthcare diagnostics. ViewsML is involved in developingimmunohistochemistry technology to streamline the diagnostic process and support research objectives efficiently. | $4.9M / Seed / Apr 20, 2026 | |
Shakudo
|
Eliminate the complexity of managing your data stack. Shakudo creates compatibility across the best-of-breed data tools for a more reliable, performant, and cost effective data stack than ever before. | $7M / Series A / Feb 17, 2026 | |
WellBeam
|
WellBeam is an operator of a connected care platform intended to help hospitals connect with third party clients. | $10M / Series A / Nov 19, 2025 | |
Grey Matter Neurosciences
|
Grey Matter Neurosciences is a neurotechnology firm developing new medical devices and drug-device combinations to treat age-related brain illnesses like dementia. | $14M / Seed / Jan 23, 2025 | |
Noetik
|
Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $40M / Series A / Aug 28, 2024 | |
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Jul 17, 2024 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Series D / Jul 17, 2024 | |
Abridge
|
Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | $150M / Series C / Feb 23, 2024 | |
Unlearn.AI
|
Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts. Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a visionof using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors.Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin.TwinRCTs provide a scientifically-sound method for using deep learning and historical patient data to improve clinical trials. | $50M / Series C / Feb 08, 2024 | |
| See all 29 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Wittington Ventures invest in?
Wittington Ventures invests primarily in Health Care, Artificial Intelligence and Biotechnology startups, most often at Series A and Series C stage. Most of the 29 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wittington Ventures?
Public channels for Wittington Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wittington Ventures?
The team at Wittington Ventures includes Darian Zigante (Senior Associate), Jim Orlando (Managing Partner) and Katie Hayes (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
